Originally founded in 1996 as Trinity Partners, Trinity Life Sciences has since grown to a global team of advisors, technical experts, data integrators, and technology innovators. The firm’s track record of consistent growth for over two decades has been fueled by a commitment to clients, passion for the life sciences, and depth of expertise in the industry. Since the beginning, Trinity Life Sciences has been evidence-forward in all analyses and recommendations, focused on quality and accuracy first and foremost. Today, having leveraged our thoughtful approach and dedication into a global organization, Trinity Life Sciences has the client footprint, deep experience, and technology solutions to have a powerful impact on clients’ business, and the industry.

Trinity Life Sciences’ approach is focused on its foundation of three: advisory services, insights & analytics, and technology. By seamlessly integrating each of these solutions, Trinity Life Sciences can meet the distinct needs of both emerging biotech firms and established pharmaceutical companies. Trinity Life Sciences can provide comprehensive end-to-end analytical and strategic support to early-stage companies, as well as tools and solutions for larger, more established life sciences clients. Trinity Life Sciences' deep industry expertise, powerful tools, and focus on evidence-based insights has enabled this firm to drive commercialization forward for some of the most innovative therapies and devices in
the industry.

Trinity Life Sciences Acquires BluePrint Research Group, December 8, 2020

Trinity Life Sciences, the leading commercial partner to the life sciences industry, announced the acquisition of New Jersey-based BluePrint Research Group. The acquisition positions Trinity as the premier partner for commercially focused strategy, insights and analytics for the life sciences industry and solidifies its global presence. BluePrint Research Group adds a London office to Trinity’s international presence as well as increases its current resources in India and the East and West Coasts of the U.S. The aligned cultures and values of both companies reflect an evidence-first approach to helping clients make critical business decisions.

Trinity Life Sciences Announces the Appointment of Rebecca McNamara as Chief Financial Officer, Sept 16, 2020

Trinity Life Sciences, a global leader in life sciences solutions, today announced the appointment of Rebecca McNamara as Chief Financial Officer (CFO) reporting directly to Dave Fitzhenry, Trinity’s CEO. Ms. McNamara has a proven track record for leading growth strategies as well as complex operational initiatives and capital allocation strategies. She joins Trinity from Boston-based Cengage where she most recently served as the Chief Integration Officer. Ms. McNamara will lead Trinity’s already world-class Operations team to even greater heights.

Trinity Life Sciences Publishes New Report Revealing What Is and Isn’t Working for Drug Launches During COVID-19, October 22, 2020

Trinity Life Sciences, a leader in global life science solutions, has published a comprehensive report entitled Launching During COVID-19, Assessing the Damage and Finding Success. The paper uncovers some surprising and concerning issues related to launching a drug during COVID-19, details case studies of drugs that have launched during the pandemic and provides important takeaways for life science companies now preparing for launch.

Trinity Life Sciences Breaks Down the Barriers for Biopharmaceutical Companies to Gain Actionable Real-World Evidence, Sept 21, 2020

Trinity Life Sciences, a leader in global life sciences solutions, introduces Trinity EvidenceFirst™, a high-value subscription service that allows biopharmaceutical companies to take advantage of real-world insights like never before. EvidenceFirst allows organizations to benefit from big, robust data without dealing with the complexities, resource requirements, and costs associated with large data sets. With EvidenceFirst, biopharmaceutical companies can now utilize real-world insights on a broader range of projects with faster turnaround times.

New In-Depth Paper Details the Assumptions Life Sciences Forecasters Need to Incorporate to Support Decision-Making in the Midst of COVID-19, July 27, 2020

Trinity Life Sciences, a leader in global life sciences solutions, published a new forecasting paper entitled Considerations for Forecasting the Spread of COVID-19: How can life sciences companies most accurately project the spread of COVID-19 to plan for the future? The paper details the steps that life sciences forecasters should take to ensure they are incorporating the right assumptions and data to most accurately project the spread of COVID-19.

Trinity Life Sciences Offers Pharma Industry’s First and Only Benchmarking-Based Launch Planning Solution, June 24, 2020

Trinity Life Sciences, a leader in global life sciences solutions, announces the pharma industry’s first and only benchmarking-based launch planning offering. The Trinity Launch Planning Solution is deeply rooted in real drug launch experience to empower superior commercialization readiness. Through proprietary technology, Trinity launch experts can quickly pull best practices from past effective launches of treatments in a specific therapeutic area based on unique benchmarking data. This allows Trinity to start with a solid base launch plan from day one, allowing more time to be spent on collaborating with cross-functional pharma launch teams on customized nuances for the plan.